



PHARMA  
SECTOR

2018 Results

REIG **20** JOFRE  
ANNIVERSARY

# DISCLOSURE

This presentation contains no confidential material and may include publicly available market information which has not been independently verified by Reig Jofre.

This information is given in summary form and does not purport to be complete. Information in this presentation should not be considered as advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling Reig Jofre shares and does not take into account your particular investment objectives, financial situation or needs.


This presentation may contain forward looking statements including statements regarding Reig Jofre's intent, belief or current expectations with respect to the businesses and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and

risk management practices. Readers are cautioned not to place undue reliance on these forward looking statements. Reig Jofre does not undertake any obligation to publicly release the result of any revisions to these forward looking statements to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside Reig Jofre's control.

Past performance is not a reliable indication of future performance.

# CONTENTS

01. REIG JOFRE TODAY	03	05. BALANCE SHEET	18
02. EVOLUTION OF THE BUSINESS AREAS	06	06. NOTES FOR THE FUTURE	27
PHARMACEUTICAL TECHNOLOGIES AREA	07	ESTRATEGIA EN TECNOLOGÍAS FARMACÉUTICAS	30
SPECIALTY PRODUCTS AREA	08	ESTRATEGIA EN PRODUCTOS DE ESPECIALIDAD	35
CONSUMER HEALTHCARE AREA	09	ESTRATEGIA EN CONSUMER HEALTHCARE	38
03. INTERNATIONAL PROGRESS	10	DESARROLLO CORPORATIVO	39
INTERNATIONAL PRESENCE	11	07. SHAREHOLDERS BASE	40
SALES BY GEOGRAPHIC AREA	12	08. LINKS TO ADDITIONAL INFORMATION	42
04. PROFIT AND LOSS ACCOUNT	13		



01

REIG JOFRE TODAY

PHARMA  
SECTOR

# PHARMACEUTICAL COMPANY FOCUSED ON THE RESEARCH, DEVELOPMENT, MANUFACTURE AND MARKETING OF PHARMACEUTICAL PRODUCTS AND NUTRITIONAL SUPPLEMENTS



## 3 GENERATIONS AT THE HEAD OF THE BUSINESS

1929

Ramon Reig Jofre  
*Founder*

1970

Joan M. Biosca  
*Founder's son-in-law*

2006

Ignasi Biosca  
*Founder's grandson and current CEO*

## YEARS SINCE FOUNDING

90

*Founded in Barcelona in 1929*

## ASSOCIATES

1056



606



450

## TICKER




RJF

*Quoted on the Spanish stock exchange's main market since 2015*




## MAIN FIGURES

Closed 2018


*\*Variation vs 2017*



## SALES EVOLUTION BY BUSINESS AREA 2018



**FORTÉ PHARMA**  
LABORATOIRES



### CDMO services

(Contract Development & Manufacturing Organization / Development and Production to third parties), driven by value-added products (derma in Sweden, injectables, biotech and antibiotics derived from penicillin)




# 02

## EVOLUTION OF THE BUSINESS AREAS

PHARMA  
SECTOR



## PHARMACEUTICAL TECHNOLOGIES AREA



### PERFORMANCE OF THE AREA

Good evolution of the **pharmaceutical technologies area** (54% of total sales), increased by 6% and contributed € 97.4 million in 2018.

Second year of strong of the antibiotic line and continued growth of the injectable and/or lyophilized products line

- Restoration of raw material supply in the **antibiotic line** that increased by 7% in 2018
- Good progression of the **sterile injectable product line** that grew by 4%
- **Investments for the expansion of production lines** amounting to € 16 million in 2018 at the plants of Toledo (antibiotics) and Barcelona (injectables)




- After the opening of the markets of Japan in 2016 and the Philippines in 2017, Reig Jofre goes a step further in its strategic internationalization plan with the opening of the Indonesian market in 2018, for the marketing of **Remikaf**, an innovative anesthetic in **Indonesia**

*In 2018, 3 new dossiers of products have been presented in the USA and 32 new product approvals have been obtained in new markets, including RemiKaf in Indonesia.*



## SPECIALTY PRODUCTS AREA




- The specialty products area decreases by 3% due to the impact of weighted reference prices in Spain, despite the increase in the units sold of these references
- During 2018 the Swedish Krona depreciated more than 3% against the Euro, which impacted consolidated sales expressed in Euros from the Dermatology area, mainly
- Additional compensation established by the Ministry of Health and Finance of Spain in compliance with the Agreement on the Expenditure Ceiling in the Innovative Pharmaceutical Industry to guarantee the sustainability of the National Health System (SNS) linked to the evolution of the Gross Domestic Product (GDP)

- The business in the United Kingdom maintains its stability despite the possible consequences of BREXIT and no significant effects are foreseen



# CONSUMER HEALTHCARE AREA




- The Consumer Healthcare area is integrated by:
  - Reig Jofre's line of nutritional supplements, **FORTÉ PHARMA** marketed mainly in France, Belgium, Spain and Portugal
  - OTCs** marketed mostly in Spain


## FOCUSSING ON FORTÉ PHARMA

- Excellent year**, of consecutive growth with new developments, accompanied by investment in marketing and advertising (reinvesting margins)
- Reorganization of business management** after integration
  - Rethinking** ranges in both product strategy and marketing
  - Working for a **better balance** of the product portfolio and greater geographical diversification
- FP France**: highlighted the good performance of its main market (+71% of the sales of this line), which represented 35% growth
- FP Iberia** (Spain and Portugal) transferred under Reig Jofre Spain management to improve synergies and optimize growth in Spain

DISTRIBUTION OF PRODUCT RANGES 2006-2018



DISTRIBUCIÓN DE VENTAS POR PAÍSES 2018



**FORTÉ PHARMA**  
LABORATOIRES

NEW DEVELOPMENTS



# 03

## INTERNATIONAL PROGRESS

PHARMA  
SECTOR



# INTERNATIONAL PRESENCE

## Sales 2018




41%  
Spain



48%  
Rest of Europe



11%  
Rest of the world



70  
world countries



Direct sales


7  
countries

96 M€

130  
commercial partners


GEOGRAPHIC  
DISTRIBUTION  
ASSOCIATES

78%  
Spain



## SALES BY GEOGRAPHICAL AREA

SALES DISTRIBUTION BY GEOGRAPHICAL AREA  
IN 2018 181 M€



- **3 new markets** in 2018: **Indonesia**, **Panama** and **South Korea**
- The **top 10 markets outside Spain** in 2017 were:
  - France (17%)
  - Sweden (7%)
  - United Kingdom and Ireland (5% respectively)
  - Benelux (3%)
  - Japan, Germany and Greece (2% respectively)
  - Portugal, Vietnam and Switzerland (1% respectively)
- Major growth in **France** (+52%), **Benelux** (+54%), **Ireland** (+36%) and **Portugal** (+16%)
- **Spain** grew by 2%, while sales in the **rest of Europe** grew by 25%
- It highlighted the significant evolution of **Africa**, which grew by 39% thanks to the sale of antibiotics and contributed 2% in 2018
- **Asia**, **Oceania** and **America** accounted for 7%, 1% and 1% of total sales, respectively



04

PROFIT AND LOSS ACCOUNT

PHARMA  
SECTOR



# P&L

SALES +7%  
**180.5 M€**

EBITDA +4%  
**16.4 M€**

PROFIT  
AFTER TAX +5%  
**9.3 M€**

PROFIT AND LOSS	2017	2018	var 18/17
<b>Turnover</b>	<b>167.983</b>	<b>180.468</b>	<b>7%</b>
Procurements	-63.971	-70.267	
Changes in inventories	-108	2.648	6%
Work carried out for fixed assets	3.743	4.824	29%
Other operating income	2.437	839	-66%
Personnel expenses	-49.355	-52.140	6%
Other operating expenses	-44.941	-49.979	11%
Depreciation and amortization	-6.829	-7.605	11%
Government grants for non-financial assets and others	65	40	-38%
Impairment and results on disposals	-11	1.192	
<b>Operating Income</b>	<b>9.011</b>	<b>10.020</b>	<b>11%</b>
Financial income	69	84	
Financial expenses	-1.077	-776	
<b>Financial Result</b>	<b>-1.008</b>	<b>-692</b>	<b>-31%</b>
Results from entities accounted by the equity method		155	
<b>Profit before taxes</b>	<b>8.003</b>	<b>9.483</b>	<b>18%</b>
Income Tax	808	-231	
<b>Net Result</b>	<b>8.811</b>	<b>9.253</b>	<b>5%</b>
<b>EBITDA</b>	<b>15.787</b>	<b>16.393</b>	<b>4%</b>

# Revenues

## ► TURNOVER

Growth in Consumer Healthcare + 22% boosts Total Sales

## ► R+D CAPITALISED

Growth in Development costs of Innovative Products, 50% of total R+D expenditures are capitalised

## ► OTHER OPERATING INCOME

Accessory Income, Royalties and others are reduced because of new distribution agreements terms

PROFIT & LOSS ACCOUNT	2017	2018	var 18/17
<b>Turnover</b>	<b>167.983</b>	<b>180.468</b>	► 7%
Procurements	-63.971	-70.267	
Changes in inventories	-108	2.648	6%
Work carried out for fixed assets	3.743	4.824	► 29%
Other operating income	2.437	839	► -66%
Personnel expenses	-49.355	-52.140	6%
Other operating expenses	-44.941	-49.979	11%
Depreciation and amortization	-6.829	-7.605	11%
Government grants for non-financial assets and others	65	40	-38%
Impairment and results on disposals	-11	1.192	
<b>Operating Income</b>	<b>9.011</b>	<b>10.020</b>	11%
Financial income	69	84	
Financial expenses	-1.077	-776	
<b>Financial Result</b>	<b>-1.008</b>	<b>-692</b>	-31%
Results from entities accounted by the equity method		155	
<b>Profit before taxes</b>	<b>8.003</b>	<b>9.483</b>	18%
Income Tax	808	-231	
<b>Net Result</b>	<b>8.811</b>	<b>9.253</b>	5%
<b>EBITDA</b>	<b>15.787</b>	<b>16.393</b>	4%

# OPEX

## ► PERSONNEL EXPENSES

Growth of +6%, main impact comes from the strengthening of Salesforce and Structure in Consumer Healthcare and higher variable compensation linked to sales performance.

## ► OTHER OPERATING EXPENSES

Increase of Marketing Expenses associated to the Consumer Healthcare line, growth of R+D expenses, and containment in the rest of business.

## ► DEPRECIATION

Impact of investment volume in 2017-2018, this effect will keep its impact in 2019-2020

## EMPLOYEES

 1056 

PROFIT & LOSS ACCOUNT	2017	2018	var 18/17
<b>Turnover</b>	<b>167.983</b>	<b>180.468</b>	<b>7%</b>
Procurements	-63.971	-70.267	
Changes in inventories	-108	2.648	6%
Work carried out for fixed assets	3.743	4.824	29%
Other operating income	2.437	839	-66%
Personnel expenses	-49.355	-52.140	► 6%
Other operating expenses	-44.941	-49.979	► 11%
Depreciation and amortization	-6.829	-7.605	► 11%
Government grants for non-financial assets and others	65	40	-38%
Impairment and results on disposals	-11	1.192	
<b>Operating Income</b>	<b>9.011</b>	<b>10.020</b>	<b>11%</b>
Financial income	69	84	
Financial expenses	-1.077	-776	
<b>Financial Result</b>	<b>-1.008</b>	<b>-692</b>	<b>-31%</b>
Results from entities accounted by the equity method		155	
<b>Profit before taxes</b>	<b>8.003</b>	<b>9.483</b>	<b>18%</b>
Income Tax	808	-231	
<b>Net Result</b>	<b>8.811</b>	<b>9.253</b>	<b>5%</b>
<b>EBITDA</b>	<b>15.787</b>	<b>16.393</b>	<b>4%</b>

# Other Results

## ► RESULTS FROM TANGIBLE ASSETS

Impact of +1,2 M€ due to the reversion of Impairment losses on industrial properties in Barcelona

## ► FINANCIAL RESULT

Improvement +0,3 M€ as a result of better financing costs, and less impact of currency variations.

## ► INCOME TAX EXPENSE

Significant impact of the R+D deduction on the effective rate, which is around 14%

PROFIT & LOSS ACCOUNT	2017	2018	var 18/17
<b>Turnover</b>	<b>167.983</b>	<b>180.468</b>	<b>7%</b>
Procurements	-63.971	-70.267	
Changes in inventories	-108	2.648	6%
Work carried out for fixed assets	3.743	4.824	29%
Other operating income	2.437	839	-66%
Personnel expenses	-49.355	-52.140	6%
Other operating expenses	-44.941	-49.979	11%
Depreciation and amortization	-6.829	-7.605	11%
Government grants for non-financial assets and others	65	40	-38%
Impairment and results on disposals	-11	1.192	►
<b>Operating Income</b>	<b>9.011</b>	<b>10.020</b>	<b>11%</b>
Financial income	69	84	
Financial expenses	-1.077	-776	
<b>Financial Result</b>	<b>-1.008</b>	<b>-692</b>	► <b>-31%</b>
Results from entities accounted by the equity method		155	
<b>Profit before taxes</b>	<b>8.003</b>	<b>9.483</b>	<b>18%</b>
Income Tax	808	-231	►
<b>Net Result</b>	<b>8.811</b>	<b>9.253</b>	<b>5%</b>
<b>EBITDA</b>	<b>15.787</b>	<b>16.393</b>	<b>4%</b>



# 05

## BALANCE SHEET

PHARMA  
SECTOR

# Assets

TOTAL CAPEX

---

**+21.7 M€**

INVENTORIES

---

**+7.0 M€**

TOTAL WORKING CAPITAL

---

**-1.5 M€**

CASH POSITION

---

**-3.4 M€**


ASSETS	2017	2018	var 18/17
Goodwill	27.745	27.598	-146
Other Intangible assets	32.521	39.121	6.600
Property, plant and equipment	46.749	54.728	7.980
Non-current investments	605	1.167	561
Non-current financial investments	716	732	16
Deferred tax assets	13.763	14.469	706
<b>Total Non-Current Assets</b>	<b>122.099</b>	<b>137.815</b>	<b>15.716</b>
Inventories	27.509	34.563	7.053
Trade and other receivables	35.161	33.856	-1.305
Other current financial assets	3.273	2.687	-586
Other current assets	3.606	2.485	-1.121
Cash and cash equivalents	11.689	8.269	-3.419
<b>Total Current Assets</b>	<b>81.238</b>	<b>81.860</b>	<b>622</b>
<b>Total Assets</b>	<b>203.337</b>	<b>219.675</b>	<b>16.338</b>



# Investments

## ► INVESTMENTS 2018

+21.7M€



## ► MAJOR PRODUCTIVE INVESTMENTS

- New Injectable Plant 7.5 M€
- Serialization Directive Investment 3.2 M€

## ► DEFERRED TAX ASSET

Tax credits and deductions not posted amounts to more than 10 M€

ASSETS	2017	2018	var 18/17
Goodwill	27.745	27.598	-146
Other Intangible assets	32.521	39.121	6.600
Property, plant and equipment	46.749	54.728	7.980
Non-current investments	605	1.167	561
Non-current financial investments	716	732	16
Deferred tax assets	13.763	14.469	706
<b>Total Non-Current Assets</b>	<b>122.099</b>	<b>137.815</b>	<b>15.716</b>
Inventories	27.509	34.563	7.053
Trade and other receivables	35.161	33.856	-1.305
Other current financial assets	3.273	2.687	-586
Other current assets	3.606	2.485	-1.121
Cash and cash equivalents	11.689	8.269	-3.419
<b>Total Current Assets</b>	<b>81.238</b>	<b>81.860</b>	<b>622</b>
<b>Total Assets</b>	<b>203.337</b>	<b>219.675</b>	<b>16.338</b>

# Current Assets

## ► CURRENT ASSETS

Increase of 4M€ without considering the reduction of Treasury, basically for the increase of raw materials

## ► CASH

Reduction of liquidity in -3,4 M€, keeping a surplus of 8,3 M€

ASSETS	2017	2018	var 18/17
Goodwill	27.745	27.598	-146
Other Intangible assets	32.521	39.121	6.600
Property, plant and equipment	46.749	54.728	7.980
Non-current investments	605	1.167	561
Non-current financial investments	716	732	16
Deferred tax assets	13.763	14.469	706
<b>Total Non-Current Assets</b>	<b>122.099</b>	<b>137.815</b>	15.716
Inventories	► 27.509	34.563	7.053
Trade and other receivables	35.161	33.856	-1.305
Other current financial assets	3.273	2.687	-586
Other current assets	3.606	2.485	-1.121
Cash and cash equivalents	► 11.689	8.269	-3.419
<b>Total Current Assets</b>	<b>81.238</b>	<b>81.860</b>	622
<b>Total Assets</b>	<b>203.337</b>	<b>219.675</b>	16.338

# Working Capital

## ► WORKING CAPITAL

40,6 M€, improvement of 1,5 M€  
Represents 82 days of sales vs 92 days in 2017

## ► INVENTORIES

Increase in stocks due to the increase of manufacturing levels previous to entry into force European Directive UE 2011/62 on February 9, 2019


## ► TRADE RECEIVABLES

Improvement of receivables management, despite of the sales increase


## ► SUPPLIERS

Increase as a consequence of inventories raise on Q4, allows to balance working capital needs

## Working Capital M€



## Working Capital Breakdown M€



# Liabilities

CAPITAL INCREASE

## 0.5 M€

FINANCIAL DEBT

## 32.7 M€

EQUITY AND LIABILITIES	2017	2018	
<b>Total Equity</b>	<b>141.559</b>	<b>149.740</b>	8.180
Capital grants	145	105	-40
Provisions	682	803	121
Financial liabilities with credit institutions	9.479	7.020	-2.459
Financial lease liabilities	7.613	14.036	6.423
Other financial liabilities	6.098	5.683	-416
Deferred tax liabilities	3.294	3.242	-51
<b>Total Non-Current Liabilities</b>	<b>27.311</b>	<b>30.889</b>	3.578
Provisions	245	45	-199
Financial liabilities with credit institutions	4.729	3.649	-1.079
Financial lease liabilities	1.351	1.536	185
Other financial liabilities	717	808	91
Trade and other payables	23.975	29.911	5.936
Current tax liabilities	972	902	-70
Other Current liabilities	2.478	2.194	-284
<b>Total Current Liabilities</b>	<b>34.467</b>	<b>39.047</b>	4.580
<b>Total Equity and Liabilities</b>	<b>203.337</b>	<b>219.675</b>	16.338

# Scrip Dividend 2018

## ► CAPITAL INCREASE

Issuing and subscription of 896.889 new shares against reserves, 1,5% of total capital

## ► CASH DIVIDEND PAYMENT

Option chosen by 12,9% of Capital

## ► TREASURY STOCK

Stock purchase of 80.000 shares in 2018 accordingly Flexible Compensation Plan for Managers.

Self owned shares: 0,45% of total

EQUITY	2017	2018	
Share Capital	32.077	32.525	448
Reserves	102.482	110.183	7.701
Treasury stock	-703	-900	-197
Other equity instruments	19	34	14
Profit attributable to the parent company	8.811	9.266	455
Exchange differences	-1.110	-1.193	-83
Other comprehensive income for assets available for sale	12	-115	-127
<b>Equity attributable to parent company</b>	<b>141.588</b>	<b>149.799</b>	8.211
Non-controlling interests	-28	-59	-31
<b>Total Equity</b>	<b>141.559</b>	<b>149.740</b>	8.180

# Financial Debt

## ► INCREASE OF FINANCIAL DEBT

**+2.7 M€**

## ► TOTAL FINANCIAL DEBT

**32.7 M€**  
 Long-term  
 Financial Debt 26,7  
 Short-term  
 Financial Debt 6,0

## ► DEBT SERVICING 2018

**-3.4 M€**

## ► INCREASE IN FINANCIAL LEASES

debt, linked to the new Barcelona Plant and Investments in Compliance with the Serialization Directive

EQUITY AND LIABILITIES	2017	2018	
<b>Total Equity</b>	<b>141.559</b>	<b>149.740</b>	8.180
Capital grants	145	105	-40
Provisions	682	803	121
Financial liabilities with credit institutions	► 9.479	7.020	-2.459
Financial lease liabilities	7.613	14.036	6.423
Other financial liabilities	6.098	5.683	-416
Deferred tax liabilities	3.294	3.242	-51
<b>Total Non-Current Liabilities</b>	<b>27.311</b>	<b>30.889</b>	3.578
Provisions	245	45	-199
Financial liabilities with credit institutions	4.729	3.649	-1.079
Financial lease liabilities	► 1.351	1.536	185
Other financial liabilities	717	808	91
Trade and other payables	23.975	29.911	5.936
Pasivos por impuestos corrientes	972	902	-70
Current tax liabilities	2.478	2.194	-284
<b>Total Current Liabilities</b>	<b>34.467</b>	<b>39.047</b>	4.580
<b>Total Equity and Liabilities</b>	<b>203.337</b>	<b>219.675</b>	16.338



# Net Debt/ EBIDTA

► TOTAL NET DEBT

24.5 M€


► DEBT/EBITDA

1.5x

► AVERAGE TIME OF DEBT

3.3 YEARS

Financial Debt M€



NET FINANCIAL DEBT	2017	2018	var
Financial Debt	29.986	32.732	2.746
Treasury	-11.689	-8.269	3.419
<b>Net Debt</b>	<b>18.297</b>	<b>24.462</b>	<b>6.165</b>
<b>Net Debt / EBIDTA</b>	<b>1,16</b>	<b>1,49</b>	












06

NOTES FOR THE FUTURE

PHARMA  
SECTOR

## STRATEGIC FOCUS BY BUSINESS AREA

		PHARMACEUTICAL TECHNOLOGIES	SPECIALTY PRODUCTS	CONSUMER HEALTHCARE
R&D	<p>Historical commitment to development. Investment of 5% of the turnover.</p> <p>Developments in medicines or medicines, Innovators or Generics Chemical or Biological</p>			
PRODUCTION	<p>Industrial commitment in specialized technologies.</p> <p>4 production plants (3 in Spain -Antibiotics, injectables and lyophilized- and 1 in Sweden - Topical dermatological products).</p>			
MARKETING & SALES	<p>Direct presence in 7 markets (Spain, France, Portugal, Benelux, United Kingdom, Nordic countries, Singapore).</p> <p>Indirect presence through distributors and licensees (+130 partners) in more than 60 countries.</p>			

## STRATEGY IN THE MANAGEMENT OF THE BUSINESS CYCLE

Reig Jofre has the ambition to develop innovative specialty products that add value to the patient's health, to the doctor or to the health systems and that could be marketed worldwide.

1

CONSUMER  
HEALTHCARE

2

PHARMACEUTICAL  
TECHNOLOGIES

3

SPECIALTY  
PRODUCTS

# STRATEGY IN PHARMACEUTICAL TECHNOLOGIES

## Antibiotics and Injectables / freeze-dried

### 1 DEMAND CREATION (products, markets, distributors)

Systematic focus during the last years

#### Product:

- Alliances with biotech startups in development phase
- Multinationals with specific needs (injectables)
- Investment in project for the development of Biosimilars (gateway to access other companies in this field)
- Systematic development of products that lose patent

#### Markets:

- Regulatory approvals in Europe, Japan (2017), Indonesia (2018), USA, Asia Pacific, Africa.
- Own registration team

#### Partners:

- Investment in continuing to grow in the more than 130 international partners

### 2 CONSTRUCTION OF PRODUCTIVE CAPACITY

Industrial investments

#### Capacity:

- Increasing available capacity
- Maintaining flexibility in batch sizes

#### Quality:

- Compliance with quality standards beyond Agency and customer requirements
- Minimize human intervention in critical phases
- Access a product with a higher price and added value

#### Productivity:

- Automated processes
- Large lots, economies of scale, cost efficiency
- Margins

### 3 SALES AND PROFITABILITY

Profitability phase following RJF business models

#### Own markets:

- Capturing 100% of the value
- Synergies with sales networks and local structures

#### Distribution:

- Sale with RJF brand
- Margin on transfer price including manufacturing cost



#### Licensees:

- Sale with own or partner's brand
- Industrial margin over manufacturing price
- Trade margins in the shared destination market

# INVESTMENT PLAN IN RJF BARCELONA 2018-2020

## EXTENSION PLANT OF STERILE INJECTABLES

- Investment: € 30M
- Financing: bank debt (80% max.), rest own resources
- Operational plant in S2-2020



### Increasing aseptic production capacities

- +50 M vials at full capacity (vs. 15M in 2016 and 3.5M in 2008)
- Access to large volume markets (USA, Indonesia, Korea ...)

### Productive efficiencies

- 20% increase in expected global productivity

### Demand created

- Products in international registration process
- Direct distribution or under closed distribution agreements

### Quality

- Isolator technology and automatic loading / unloading of lyophilizers guarantees the critical phases of aseptic production without human contact
  - Minimizes contamination risk
- Products possibility of
  - biological or chemical basis
  - innovative or out of patent
  - research or comercial purposes

### Energy Efficiencies

- Contribution to a cleaner and more sustainable economy thanks to the design of the new plant with energy efficiency criteria



# INVESTMENT PLAN IN RJF TOLEDO 2016-2018


## INVESTMENT

- € 10M for new sterile injectable antibiotic line and expansion space for a future second line
- Operational in 2019.






- Current plant close to 100% capacity (produces 15% of the antibiotics units consumed in Spain and 25% of the penicillin derivatives - beta-lactam -)
- Investment needed to access new markets that are in registration process
- 33% increase capacity of (sterile injectable penicillin), to reach 25M vials per year
- Greater volume allows absorbing expenses of both quality and administrative structure and optimizing unit margins
- The cutting-edge technology of the new line allows access to markets with higher profitability
- RJF entry model in the USA will allow the capture of industrial (similar to Europe) and commercial (above Europe) margins

## R&D INVESTMENTS



# PHARMACEUTICAL TECHNOLOGIES PIPELINE

	PRODUCT	DESCRIPTION	
<b>INNOVATIVE</b> + Innovation + Risk + Collaborations + Potential return	Biosimilar	Syna Therapeutics (Joint Venture: RJF & LeanBio)	
	Acinetoclinic Vaccine injectable lyophilized	First vaccine against resistance to A. Baumannii	
	P0512 beta-lactam antibiotic	Mucoadhesive nanoformulation of antibiotic against H.Pylori	
<b>GENERIC</b> - Innovation - Risk + Specific opportunities by market + In-house developments = Potential return	6 projects of freeze-dried antibiotics, injectables and injectables under development in 2018. · 4 in phase of registration at the year-end		
	Aseptic production specialist		

# STRATEGY IN SPECIALTY PRODUCTS

## Dermatology and Gynecology

### 1 PORTFOLIO GENERATION Innovation

#### Balanced portfolio:

- Risk / Investment / Time
- Radical / Incremental
- Science / Value proposition
- Internal / External

#### Regulatory strategy and Market Access:

- Medical-marketing proposal
- Medicines, health products, cosmetics and nutritional supplements.

#### Open and collaborative innovation:

- Connection with the health ecosystem
- Collaborations with academic centers, hospitals and Start-Ups Biotech allow different models of co-development.
- International innovation hubs

### 2 INVESTMENT IN R&D Development with scientific evidence

#### Areas of expertise:

- Skin / nails / hair
- Gynecology / women's health
- With special focus on infections

#### Prescription-Recommendation:

- Medicines with indication
- Borderline products between specialist and consumer
- Solid value proposition

#### Flexible team oriented to create value:

- Specialized development in all sites
- Galenica and analysis
- Clinical and pre-clinical
- Regulator

#### Investments in concept tests:

- *In vitro* and *in vivo* assays to validate activity
- Clinical trials

### 3 SALES AND PROFITABILITY Value proposal

#### Medical-marketing proposal

- Strategy adapted to each market / Country

#### Commercial teams in 7 markets:

- Visit to medical specialists
- Pharmacies
- Key Account Managers, hospitals

#### Markets:

- International sales with RJF brand in its own markets
- Distributors in non-owned markets

# SPECIALTY PRODUCTS

## KEY R&D EVENTS IN 2018

### Dermatology / Gynecology

#### MILESTONES IN CLINICAL TRIALS

##### Clinical trials started in 2018:

- P0285: Nail regenerator
- P0283: Nutritional Supplement for men to improve the fertility ratio and prevent repeated abortions

##### Finalized Recruitment:

- P0265: Treatment for skin infections

##### Clinical trials in progress:



# SPECIALTY PRODUCTS PIPELINE

	PRODUCT AND DESCRIPTION
<b>MEDICINES</b>  + Innovation + Risk + Collaborations + Potential return	3 projects
	Skin, hair and nail conditions
	3 in collaboration
<b>MEDICAL DEVICE, NUTRITIONAL SUPPLEMENTS, COSMETICS</b>  + Innovation + Risk + Collaboration + Potential return	8 projects
	3 women's health and reproduction
	4 Skin, hair and nail conditions
<b>GENERIC MEDICINES</b>  - Innovation - Risk + Specific opportunities by market + In-house developments = Potential return	5 collaborations
	3 projects
	Skin conditions

# STRATEGY IN CONSUMER HEALTHCARE

## Nutritional supplements / OTC



### SITUATION

- Health market vs. market of the disease
- Consumers are well informed and concerned about health care and prevention
- The scientific / technical knowledge we have of both the disease market and the prescriber opens the opportunity for RJF to transfer that model to the health and consumption market

### WHAT RJF SHOULD OFFER IN THE CONSUMER HEALTH MARKET

- Trusted brands for the consumer
- Product with scientific-technical basis (clinical support, whether regulatory or not)
- Clear value proposition for the consumer
  - and eventually also for a possible prescriber - physicians or new health prescribers, physiotherapist, osteopath ...
- Ability to identify trends and launch products quickly
- Natural alternative to medicines: efficacy without any risk of side effects

## CORPORATE DEVELOPMENT

- Active policy to identify non-organic growth opportunities
- Incorporation of businesses with strategic fit and adequate cash generation avoiding overpricing
- Search in areas of specialty products and Consumer Healthcare
  - Consolidation of presence in existing markets (Spain, France, Nordic countries and United Kingdom)
  - Opportunities in other strategic markets
- Second priority: acquisition of industrial businesses specialized in other pharmaceutical technologies





07


SHAREHOLDERS BASE

PHARMA  
SECTOR

# SHAREHOLDERS BASE

at 31/12/2018


REIG JOFRE  
INVESTMENTS, S.L.  
*Investment company of the Reig family*



\*Food company, quoted on the main market of the Spanish stock Exchange.  
Former controlling shareholder in Natraceutal.

## RJF initiatives to increase the free float:

- During 2018 the free float increased by 6.4% (from 14.7% to 15.7%)
- During 2017, the free float increased by 8.2% (from 13.5% to 14.7%)



## LINKS TO ADDITIONAL INFORMATION

▶ Last news:  
[www.reigjofre.com/en/news](http://www.reigjofre.com/en/news)

▶ Webcast of results:  
[www.reigjofre.com/en/investors/webcasts](http://www.reigjofre.com/en/investors/webcasts)

▶ Subscription Center:  
[www.reigjofre.com/en/subscription-center](http://www.reigjofre.com/en/subscription-center)



Av. de les Flors  
08970 Sant Joan Despi  
Barcelona, Spain  
T. +34 93 480 67 10

[www.reigjofre.com](http://www.reigjofre.com)

**Relationship investors**  
[investors@reigjofre.com](mailto:investors@reigjofre.com)